Nonclinical evaluation of HBG1/2 and BCL11A as genome editing targets for the treatment of β-hemoglobinopathies

Janoudi, Tusneem; Jagdale, Mrunali; Wu, Meng; Gorlla, Sanjana; Zhang, Peisheng; Shao, Ying; Li, Li; Bowley, Sheryl R.; Marco, Eugenio; Chang, Kai-Hsin

doi:10.1182/bloodadvances.2024014040

This content is only available as a PDF.

2024

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Nonclinical evaluation of HBG1/2 and BCL11A as genome editing targets for the treatment of β-hemoglobinopathies

Article PDF first page preview

Supplemental data

Cited By

Email alerts

ASH Publications

American Society of Hematology

Nonclinical evaluation of HBG1/2 and BCL11A as genome editing targets for the treatment of β-hemoglobinopathies

Article PDF first page preview

Supplemental data

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only